This study explores HIV-positive gay and bisexual men's (GBM) understanding of human papillomavirus (HPV) and the HPV vaccine.
Methods:
Researchers conducted 15 in-depth interviews with HIV-positive GBM between the ages of 18–30 years old.
Results:
Two participants had received a single dose of the HPV vaccine. Otherwise, the majority of participants had either never heard of the HPV vaccine or they perceived it as a resource for women only. Other commonly cited barriers to getting the vaccine included lack of provider recommendation to complete the vaccine series and vaccine costs.
Conclusions:
Future provider-driven interventions should focus on increasing HPV vaccine among age-eligible HIV-positive GBM.
Get full access to this article
View all access options for this article.
References
1.
ChaturvediAK: Beyond cervical cancer: Burden of other HPV-related cancers among men and women. J Adolesc Health, 2010; 46:S20–S26.
2.
VidelaS, DarwichL, CañadasMP, et al.: Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis, 2013; 40:3–10.
3.
MuñozN, CastellsaguéX, de GonzálezAB, GissmannL: Chapter 1: HPV in the etiology of human cancer. Vaccine, 2006; 24:S1–S10.
4.
MooijSH, van der KlisFR, van der SandeMA, et al.: Seroepidemiology of high-risk HPV in HIV-negative and HIV-infected MSM: The H2M study. Cancer Epidemiol Biomarkers Prev, 2013; 22:1698–1708.
5.
PetroskyE, BocchiniJAJr, HaririS, et al.: Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep, 2015; 64:300–304.
6.
SaraiyaM, UngerER, ThompsonTD, et al.: US assessment of HPV types in cancers: Implications for current and 9-valent HPV vaccines. J Natl Cancer Inst, 2015; 107:djv086.
7.
MeitesE, KempeA, MarkowitzLE: Use of a 2-dose schedule for human papillomavirus vaccination—Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep, 2016; 65:1405–1408.
8.
FaustH, ToftL, SehrP, et al.: Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine, 2016; 34:1559–1565.
9.
GiacometV, PenaginiF, TrabattoniD, et al.: Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine, 2014; 32:5657–5661.
10.
HernandezAL, EfirdJT, HollyEA, et al.: Incidence of and risk factors for type-specific anal human papillomavirus infection among HIV-positive MSM. AIDS, 2014; 28:1341–1349.
11.
DeshmukhAA, ChhatwalJ, ChiaoEY, et al.: Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men. Clin Infect Dis, 2015; 61:1527–1535.
12.
OliverSE, HootsBE, Paz-BaileyG, et al.: Increasing human papillomavirus vaccine coverage among men who have sex with men—National HIV Behavioral Surveillance, United States, 2014. J Acquir Immune Defic Syndr, 2017; 75:S370–S374.
13.
GilbertP, BrewerNT, ReiterPL, et al.: HPV vaccine acceptability in heterosexual, gay, and bisexual men. Am J Mens Health, 2011; 5:297–305.
14.
ReiterPL, McReeAL, KatzML, PaskettED: Human papillomavirus vaccination among young adult gay and bisexual men in the United States. Am J Public Health, 2015; 105:96–102.
15.
EatonEF, KulczyckiA, SaagM, et al.: Immunization costs and programmatic barriers at an urban HIV clinic. Clin Infect Dis, 2015; 61:1726–1731.
PalefskyJM, GiulianoAR, GoldstoneS, et al.: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med, 2011; 365:1576–1585.
18.
SwedishKA, FactorSH, GoldstoneSE: Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: A nonconcurrent cohort study. Clin Infect Dis, 2012; 54:891–898.
